KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 123 filers reported holding KALA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $97,000 | -9.3% | 436,800 | +22.8% | 0.00% | – |
| Q2 2022 | $107,000 | -70.4% | 355,600 | +35.9% | 0.00% | – |
| Q1 2022 | $361,000 | +137.5% | 261,700 | +107.9% | 0.00% | – |
| Q4 2021 | $152,000 | -65.1% | 125,900 | -24.2% | 0.00% | -100.0% |
| Q3 2021 | $435,000 | -33.5% | 166,100 | +72.1% | 0.00% | 0.0% |
| Q4 2020 | $654,000 | +261.3% | 96,516 | +462.0% | 0.00% | – |
| Q2 2020 | $181,000 | -82.3% | 17,175 | -85.3% | 0.00% | -100.0% |
| Q1 2020 | $1,024,000 | +296.9% | 116,479 | +187.6% | 0.00% | – |
| Q2 2019 | $258,000 | -72.1% | 40,500 | -63.8% | 0.00% | -100.0% |
| Q1 2019 | $926,000 | -34.9% | 112,000 | -61.5% | 0.00% | -50.0% |
| Q4 2018 | $1,423,000 | +226.4% | 291,061 | +558.5% | 0.00% | – |
| Q3 2018 | $436,000 | – | 44,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,727,751 | $4,527,000 | 3.67% |
| RA Capital Management | 10,874,613 | $28,491,000 | 0.40% |
| ACT CAPITAL MANAGEMENT, LLC | 190,000 | $498,000 | 0.26% |
| Samsara BioCapital, LLC | 601,162 | $1,575,000 | 0.25% |
| Orbimed Advisors | 3,438,998 | $9,010,000 | 0.10% |
| Towercrest Capital Management | 122,500 | $321,000 | 0.06% |
| Knights of Columbus Asset Advisors LLC | 236,757 | $620,000 | 0.06% |
| Matisse Capital | 56,100 | $147,000 | 0.05% |
| Taylor Wealth Management Partners | 43,990 | $115,000 | 0.04% |
| SYMONS CAPITAL MANAGEMENT INC | 14,346 | $37,000 | 0.02% |